UBA3 reduction sensitizes cancer cells to NAE inhibitors
Open Access
- 29 April 2026
- journal article
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 9 (7) , e202503589
Abstract
The NEDD8-activating enzyme (NAE), comprising NAE1 and UBA3, is an anticancer target. The relative contribution of each of these subunits toward NAE inhibitor (NAEi) efficacy remains unclear. We demonstrated a profound interdependence of NAE1 and UBA3 expression. UBA3 reduction augmented NAEi sensitivity, whereas its overexpression led to decreased sensitivity. UBA3 deficiency enhanced RKO xenograft sensitivity to SOMCL-19-133 (NAEi), which was reversed by UBA3 restoration. Cells with naturally low UBA3 expression were highly NAEi-sensitive. The criticality of UBA3 in NAEi sensitivity is not completely unexpected given that the ability of NAEi to directly bind to UBA3 is known. TCGA data showed that rectum adenocarcinoma patients with low UBA3 mRNA had poorer prognoses, and 27.16% of tumors expressed low UBA3 mRNA. We propose that low UBA3 expression may serve as a NAEi sensitivity biomarker, particularly given that MLN4924 (NAEi) phase 3 failures may be due to a lack of patient stratification. Therefore, our key findings, on the criticality of UBA3 in NAEi sensitivity, underpin future clinical evaluations.Keywords
Funding Information
- National Natural Science Foundation of China (82073875)
- State Key Laboratory of Drug Research, Chinese Academy of Sciences
This publication has 29 references indexed in Scilit:
- The Absence of PTEN in Breast Cancer Is a Driver of MLN4924 ResistanceFrontiers in Cell and Developmental Biology, 2021
- A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumorsInvestigational New Drugs, 2021
- Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AMLLeukemia, 2021
- E1 Enzymes as Therapeutic Targets in CancerPharmacological Reviews, 2021
- Hepatic neddylation targets and stabilizes electron transfer flavoproteins to facilitate fatty acid β-oxidationProceedings of the National Academy of Sciences, 2020
- Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AMLBlood, 2018
- Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 studyBritish Journal of Haematology, 2015
- A Gatekeeper Residue for NEDD8-Activating Enzyme Inhibition by MLN4924Cell Reports, 2012
- Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In SituMolecular Cell, 2010
- An inhibitor of NEDD8-activating enzyme as a new approach to treat cancerNature, 2009